Technical Analysis for MACK - Merrimack Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 6.0 1.69% 0.10
MACK closed up 1.69 percent on Friday, May 17, 2019, on 26 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical MACK trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Outside Day Range Expansion 0.00%
20 DMA Resistance Bearish 1.69%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.69%
Earnings Movers Other 0.67%
Outside Day Range Expansion 0.67%
Narrow Range Bar Range Contraction 2.56%
NR7 Range Contraction 2.56%

Older signals for MACK ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer in the United States. The company uses its Network Biology proprietary systems biology-based approach to biomedical research. Its therapeutic oncology candidates in clinical development include MM-398, a stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan, which is in multiple ongoing Phase I, Phase II, Phase III clinical trials for various cancers; MM-121, a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in cancer, which is in multiple ongoing Phase I and Phase II clinical trials; and MM-111, a bispecific antibody designed to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 cell receptor, which is in multiple ongoing Phase I and Phase II clinical trials. The company's product candidates also include MM-302, a nanotherapeutic encapsulation of doxorubicin with attached antibodies that target the ErbB2 (HER2) receptor in Phase 1 clinical trial in patients with advanced ErbB2 positive breast cancer; MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, which is in Phase I clinical trial; and MM-141, a human tetravalent bispecific antibody designed to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth factor 1 receptor(IGF-1R) and ErbB3, which is in Phase 1 clinical trial. It has collaboration and license agreements with Sanofi; Dyax Corp.; PharmaEngine, Inc.; Adimab LLC; University of California; U.S. Public Health Service; and Selexis SA. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Medicine Biopharmaceutical Cancer Treatment Of Cancer Antibodies Cancers Chemotherapy Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Her2/Neu University Of California Erb B3 Mm 151
Is MACK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 10.535
52 Week Low 3.34
Average Volume 62,320
200-Day Moving Average 5.3561
50-Day Moving Average 6.3508
20-Day Moving Average 6.048
10-Day Moving Average 5.917
Average True Range 0.3019
ADX 12.89
+DI 19.6194
-DI 18.6326
Chandelier Exit (Long, 3 ATRs ) 5.8343
Chandelier Exit (Short, 3 ATRs ) 6.4457
Upper Bollinger Band 6.4774
Lower Bollinger Band 5.6186
Percent B (%b) 0.44
BandWidth 14.199735
MACD Line -0.0976
MACD Signal Line -0.1038
MACD Histogram 0.0063
Fundamentals Value
Market Cap 79.67 Million
Num Shares 13.3 Million
EPS 32.12
Price-to-Earnings (P/E) Ratio 0.19
Price-to-Sales 1.06
Price-to-Book 1.44
PEG Ratio 0.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.51
Resistance 3 (R3) 6.49 6.31 6.43
Resistance 2 (R2) 6.31 6.18 6.32 6.40
Resistance 1 (R1) 6.15 6.10 6.23 6.17 6.37
Pivot Point 5.97 5.97 6.01 5.98 5.97
Support 1 (S1) 5.81 5.84 5.89 5.83 5.63
Support 2 (S2) 5.63 5.76 5.64 5.60
Support 3 (S3) 5.47 5.63 5.58
Support 4 (S4) 5.49